Udvalget fandt, at fordelene ved Tarceva opvejede risiciene til disse former for kræft og til metastatisk pancreascancer.
The committee decided that Tarceva’ s benefits are greater than its risks for these types of cancer, as well as for metastatic cancer of the pancreas.